Quality of life and productivity loss in patients with ankylosing spondylitis using tumor necrosis factor inhibitors

Abstract

Quality of life and productivity loss in patients with ankylosing spondylitis using tumor necrosis factor inhibitorsDear Editor,We have read with great interest the article by Lee et al 1 reporting a comprehensive understanding of the real-world treatment patterns of tumor necrosis factor inhibitor (TNFi) in patients with ankylosing spondylitis (AS) and productivity loss, treatment satisfaction, and associated factors. There are 4 TNFi considered in this study, including infliximab, adalimumab, etanercept, and golimumab. The advantage of this study was that the data collected is extremely detailed and novel, including annual household income, education, and body mass index, which helps us know more about this issue from a different perspective and may arouse much attention to the issue that has usually been neglected previously. However, we found some concerns that we hope to be answered.